Kepos Capital LP Clene Inc. Transaction History

Kepos Capital LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.46 - $0.87 $17,791 - $33,649	-38,678 Reduced 22.75%	131,322 $65,000
Q2 2023 Aug 10, 2023	SELL	$0.78 - $1.22 $136,053 - $212,800	-174,427 Reduced 50.64%	170,000 $150,000
Q4 2022 Feb 13, 2023	SELL	$0.92 - $1.11 $51,127 - $61,686	-55,573 Reduced 13.89%	344,427 $344,000
Q3 2022 Nov 14, 2022	SELL	$0.33 - $4.83 $66,000 - $966,000	-200,000 Reduced 33.33%	400,000 $1.12 Million
Q2 2022 Aug 12, 2022	SELL	$2.1 - $4.12 $105,000 - $206,000	-50,000 Reduced 7.69%	600,000 $1.51 Million

Q3 2021 Nov 12, 2021	BUY	$6.83 - $13.58 $683,000 - $1.36 Million	100,000 Added 18.18%	650,000 $4.44 Million
Q2 2021 Aug 12, 2021	BUY	$6.98 - $13.33 $2.44 Million - $4.67 Million	350,000 Added 175.0%	550,000 $6.18 Million
Q1 2021 May 13, 2021	SELL	$6.39 - $16.3 $404,071 - $1.03 Million	-63,235 Reduced 24.02%	200,000 $2.56 Million
Q4 2020 Feb 12, 2021	BUY	$10.75 - $12.97 $2.83 Million - $3.41 Million	263,235 New	263,235 $2.37 Million

7.44M

48.1K

160K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $21M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

Stay updated on Kepos Capital LP with notifications on news.